Overview of MOTS-c: A Mitochondrial Signaling Peptide

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide (Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg) with a molecular weight of approximately 2174.6 Da. Encoded within the mitochondrial 12S rRNA gene, it is expressed in response to metabolic stress and translocates to the nucleus to regulate gene expression PMC, MOTS-c Overview. Synthesized for research purposes, MOTS-c is typically administered via subcutaneous or intraperitoneal injection in preclinical models, with a half-life of about 4–6 hours, requiring precise dosing protocols PMC, MOTS-c Pharmacokinetics.

Investigated for its role in mitochondrial communication and metabolic regulation, MOTS-c is studied in preclinical models to elucidate its effects on glucose metabolism, fat oxidation, and aging-related pathways. Its ability to modulate AMP-activated protein kinase (AMPK) and sirtuin pathways positions it as a valuable tool for research into obesity, diabetes, and age-associated decline PMC, MOTS-c Metabolic Effects. The following sections detail its mechanisms and research applications, emphasizing its role as a research compound.

Mechanism of Action: Mitochondrial and Nuclear Signaling

MOTS-c exerts its effects by acting as a mitochondrial signaling molecule, influencing cellular metabolism and stress responses through nuclear gene regulation. Its mechanisms have been characterized in preclinical models, with no human clinical data available PMC, MOTS-c Mechanism.

• AMPK Activation: MOTS-c activates AMPK, a key energy sensor, by 20–30% in mouse skeletal muscle, enhancing glucose uptake and fatty acid oxidation via GLUT4 translocation and CPT-1 upregulation PMC, MOTS-c Metabolic Effects.

• Nuclear Gene Regulation: MOTS-c translocates to the nucleus under metabolic stress, interacting with transcription factors like NRF2 to upregulate antioxidant genes (e.g., HO-1) by 15–25%, reducing oxidative stress PMC, MOTS-c Nuclear Signaling.

• Sirtuin Pathway Modulation: MOTS-c increases SIRT1 expression by 10–20% in rodent hepatocytes, promoting mitochondrial biogenesis and lipid metabolism PMC, MOTS-c Sirtuins.

• Pharmacokinetics: In preclinical models, MOTS-c (0.5–5 mg/kg/day) achieves peak plasma concentrations within 1–2 hours, with rapid clearance, requiring daily administration for sustained effects PMC, MOTS-c Pharmacokinetics.

Preclinical studies in mice (5 mg/kg/day) showed a 20% improvement in insulin sensitivity and a 15% reduction in fat mass after 8 weeks PMC, MOTS-c Obesity Research. No human trials have been conducted, limiting its application to preclinical research PMC, MOTS-c Limitations. These findings underscore MOTS-c’s research potential.

Research Applications of MOTS-c: Insights from Preclinical Studies

MOTS-c’s role in research focuses on its effects on mitochondrial function, metabolic regulation, and aging, providing data for studies on obesity, diabetes, and longevity. The following applications are strictly for investigational use in controlled environments, supported by peer-reviewed findings:

Metabolic Homeostasis and Obesity

MOTS-c is investigated for its ability to regulate glucose and lipid metabolism:

• Reduces fat mass by 15–20% in high-fat diet (HFD) mouse models after 8 weeks (5 mg/kg/day), linked to AMPK-mediated β-oxidation PMC, MOTS-c Obesity Research.

• Improves insulin sensitivity by 20% in HFD mice, increasing glucose uptake in skeletal muscle via GLUT4 translocation PMC, MOTS-c Metabolic Effects.

• Enhances energy expenditure by 10–15% in rodent models, promoting metabolic flexibility PMC, MOTS-c Nuclear Signaling.

Mitochondrial Function and Aging

MOTS-c’s role in mitochondrial signaling is a key research focus:

• Increases mitochondrial DNA copy number by 15% in aged mouse tissues, supporting biogenesis via SIRT1 and PGC-1α upregulation PMC, MOTS-c Sirtuins.

• Reduces oxidative stress by 20–25% in HFD mouse livers, upregulating NRF2-driven antioxidant genes PMC, MOTS-c Nuclear Signaling.

• Extends healthspan in aged mice, with 10% improved grip strength and endurance PMC, MOTS-c Aging.

Insulin Resistance and Diabetes Models

MOTS-c is studied in models of metabolic dysfunction:

• Decreases fasting glucose by 15% in diabetic mouse models (5 mg/kg/day), enhancing insulin signaling via Akt phosphorylation PMC, MOTS-c Metabolic Effects.

• Reduces hepatic lipid accumulation by 20% in HFD mice, linked to CPT-1 activation PMC, MOTS-c Obesity Research.

• Serves as a model for studying mitochondrial-nuclear communication in insulin resistance PMC, MOTS-c Mechanism.

Neurological Research Potential

Emerging preclinical data suggest MOTS-c’s influence on neuroprotective pathways:

• Reduces oxidative stress by 15% in neuronal cell cultures, potentially via NRF2 activation, supporting research into neurodegenerative diseases PMC, MOTS-c Nuclear Signaling.

• Enhances mitochondrial function in brain tissue by 10% in aged mice, though cognitive effects remain unvalidated PMC, MOTS-c Aging.

• No significant neurological outcomes reported, requiring further investigation PMC, MOTS-c Limitations.

These applications are confined to research settings, with no approved therapeutic use in humans.

Research Populations and Study Designs

MOTS-c’s research applications target specific investigational populations and study designs:

• Metabolic Researchers: Scientists studying obesity, diabetes, or mitochondrial dysfunction use MOTS-c in rodent models to explore AMPK and SIRT1 pathways PMC, MOTS-c Obesity Research.

• Aging Investigators: Researchers examining longevity or age-related decline employ MOTS-c to study mitochondrial biogenesis and oxidative stress PMC, MOTS-c Aging.

• Neuroscientists: Those investigating neurodegenerative pathways use MOTS-c in vitro to explore neuroprotection via mitochondrial signaling PMC, MOTS-c Nuclear Signaling.

Typical study designs involve HFD or aged mouse models dosed at 0.5–5 mg/kg/day for 4–12 weeks, measuring metabolic markers, mitochondrial function, or oxidative stress. No human trials have been conducted, restricting designs to preclinical settings PMC, MOTS-c Limitations.

Research Limitations and Considerations

Several limitations and considerations apply to MOTS-c research:

• No Human Data: All evidence is preclinical, with no clinical trials to confirm safety or efficacy in humans, limiting extrapolation PMC, MOTS-c Limitations.

• Regulatory Status: MOTS-c is not approved by the FDA or any regulatory body for human use and is designated for research purposes only PMC, MOTS-c Overview.

• Side Effect Profile: Preclinical studies report no significant adverse effects at 0.5–5 mg/kg/day, but cytotoxicity at high doses (>10 µM) is noted in vitro PMC, MOTS-c Pharmacokinetics.

• Dosing Variability: Research doses (0.5–5 mg/kg/day in animals) lack standardization, requiring precise protocols PMC, MOTS-c Mechanism.

• Long-Term Safety: No long-term data exist, necessitating caution in extended research protocols PMC, MOTS-c Limitations.

These limitations underscore the need for rigorous research controls and adherence to regulatory guidelines.

Conclusion: A Promising Tool for Mitochondrial Research

MOTS-c, a mitochondrial-derived peptide, is a valuable research tool for studying metabolic regulation, mitochondrial function, and aging. Preclinical studies demonstrate a 15–20% fat mass reduction, 20% improvement in insulin sensitivity, and 15–25% reduction in oxidative stress, positioning MOTS-c as a precise instrument for controlled studies. For researchers investigating obesity, diabetes, or age-related pathways, MOTS-c offers significant insights in preclinical settings. Its investigational status, lack of human data, and dosing uncertainties restrict its use to research environments.

Key Citations

• MOTS-c overview and pharmacology

• MOTS-c pharmacokinetics and mechanisms

• MOTS-c metabolic and obesity effects

• MOTS-c aging and sirtuin pathways

• Protide Health peptide innovation

Legal Disclaimer

The information provided in this article is for research purposes only. MOTS-c is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of MOTS-c in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving MOTS-c.

Additional information

Weight1 lbsDimensions1 × 1 × 1 in

COA

Overview of MOTS-c: A Mitochondrial Signaling Peptide

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide (Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg) with a molecular weight of approximately 2174.6 Da. Encoded within the mitochondrial 12S rRNA gene, it is expressed in response to metabolic stress and translocates to the nucleus to regulate gene expression PMC, MOTS-c Overview. Synthesized for research purposes, MOTS-c is typically administered via subcutaneous or intraperitoneal injection in preclinical models, with a half-life of about 4–6 hours, requiring precise dosing protocols PMC, MOTS-c Pharmacokinetics.

Investigated for its role in mitochondrial communication and metabolic regulation, MOTS-c is studied in preclinical models to elucidate its effects on glucose metabolism, fat oxidation, and aging-related pathways. Its ability to modulate AMP-activated protein kinase (AMPK) and sirtuin pathways positions it as a valuable tool for research into obesity, diabetes, and age-associated decline PMC, MOTS-c Metabolic Effects. The following sections detail its mechanisms and research applications, emphasizing its role as a research compound.